



T2R Bitter Taste Receptors: From Gustation to Systemic Physiology and Therapeutic Potential for Better Bitter Blocker Research

I. T2R Bitter Taste Receptors: Definition, Structure, and Gustatory Role

A. Defining T2Rs within the GPCR Superfamily

Taste 2 Receptors (T2Rs), also designated TAS2Rs, constitute a distinct family of G protein-coupled receptors (GPCRs) primarily recognized for their role in mediating the perception of bitter taste in vertebrates.¹ These receptors belong to the extensive GPCR superfamily, a group of integral membrane proteins characterized by their seven transmembrane (7TM) domains.¹ GPCRs are fundamental to cellular signaling, translating extracellular stimuli into intracellular responses, and notably, they represent the targets for over half of all currently marketed pharmaceutical drugs, underscoring their physiological and pharmacological importance.¹

While T2Rs share the characteristic 7TM architecture of GPCRs³, they exhibit low sequence homology (often less than 30%) with the largest and most extensively studied GPCR subgroup, the Class A (rhodopsin-like) receptors.⁶ This limited similarity makes their precise classification within the broader GPCR family somewhat ambiguous and presents significant challenges for structural prediction using homology modeling based on Class A templates.¹⁰ The structural uniqueness of T2Rs compared to Class A GPCRs necessitates specific research approaches. Because GPCRs are such a prominent drug target class, the distinct nature of T2Rs suggests that strategies effective for designing Class A GPCR modulators may not be directly transferable. Developing drugs that selectively target T2Rs requires a deep understanding of their specific structural features and activation mechanisms, distinct from their Class A counterparts.⁶ This presents both a hurdle, due to the relative lack of structural data compared to Class A, and an opportunity for developing novel





therapeutic agents with potentially unique modes of action.

B. Canonical Function in Bitter Taste Perception

The quintessential and originally identified function of T2Rs is the detection of bitter-tasting compounds within the oral cavity, specifically on the tongue, soft palate, and pharynx.¹ These receptors are strategically located on the apical surface of specialized neuroepithelial cells known as Type II taste receptor cells (TRCs), which are clustered within taste buds.¹ Positioned to monitor the contents of ingested food and drink, T2Rs act as crucial sentinels.²

Upon binding a compatible bitter ligand, T2Rs initiate an intracellular signaling cascade.² This cascade culminates in the depolarization of the TRC and the subsequent release of adenosine triphosphate (ATP) as a neurotransmitter.¹ The released ATP activates purinergic receptors located on afferent gustatory nerve fibers, which then transmit the signal to the gustatory centers in the brain, leading to the conscious perception of bitterness.¹

This gustatory function is widely considered a critical protective mechanism that evolved to warn organisms against the ingestion of potentially harmful or toxic substances.¹ Many naturally occurring toxins, particularly secondary metabolites produced by plants such as alkaloids and glycosides, elicit a bitter taste, and the aversive response triggered by T2R activation helps prevent poisoning.¹⁶ This fundamental role in toxin avoidance is believed to be a major evolutionary driver shaping the T2R gene family and its function.¹⁹

C. Fundamental Structural Characteristics

T2R proteins are typically composed of 290 to 333 amino acids.⁶ They exhibit the canonical GPCR structure, featuring seven hydrophobic transmembrane α -helices (TM1–TM7) that span the cell membrane.³ These helices are connected by three intracellular loops (ICLs) and three extracellular loops (ECLs), along with a relatively





short extracellular N-terminus and an intracellular C-terminus.³

A notable feature of the TAS2R genes encoding these receptors is that their coding regions are generally compact, approximately 1 kilobase (kb) in length, and lack introns.² This intronless structure is relatively uncommon among vertebrate GPCR genes and likely facilitates evolutionary processes such as gene duplication. Mechanisms like unequal crossing-over or retrotransposition can more readily duplicate compact, intronless genes, potentially contributing to the observed rapid expansion and contraction (birth-and-death evolution) and the significant variation in T2R gene family size seen across different species.²⁰

Structurally, T2Rs display some distinctions compared to Class A GPCRs. While the core 7TM bundle represents a conserved scaffold necessary for signal transduction, indicating functional constraint, the loops connecting the helices show different patterns of conservation. T2Rs often possess shorter ECL2 and ICL3 regions relative to many Class A receptors.⁶ Interestingly, the intracellular loops (ICLs), which are crucial for G protein coupling, exhibit a higher degree of sequence similarity among different T2R family members compared to the ICLs of Class A GPCRs.⁶ Conversely, the extracellular loops (ECLs), particularly ECL2 and ECL3, along with residues on the extracellular faces of the TM helices (especially TM3, TM4, TM5, TM6, TM7), are more divergent.³ This divergence in the extracellular regions, which form the primary ligand-binding pocket, is thought to be essential for the recognition of the vast and chemically diverse array of bitter compounds, reflecting evolutionary adaptation to different chemical environments and dietary niches.³

Despite significant progress in functional characterization, a major challenge in the field is the lack of experimentally determined high-resolution structures (e.g., via X-ray crystallography or cryo-electron microscopy) for any T2R.⁹ Consequently, our understanding of T2R structure, ligand binding modes, and activation mechanisms relies heavily on computational approaches, primarily molecular modeling guided by mutagenesis data.³





II. Molecular Mechanisms of Bitter Sensing

A. Ligand Binding and Receptor Activation Dynamics

The process of bitter taste transduction begins with the binding of a bitter compound (ligand) to its cognate T2R(s) located on the surface of Type II taste receptor cells.² The binding sites for these ligands are generally located within the transmembrane domains or involve residues in the extracellular loops, forming a pocket accessible from the extracellular environment.³ This interaction is analogous to ligand binding in other GPCRs, where binding typically occurs within the transmembrane bundle or near the extracellular surface.⁷

Ligand binding induces a conformational change in the T2R protein.⁷ This structural rearrangement alters the intracellular face of the receptor, enabling it to interact with and activate its associated heterotrimeric G protein. Specifically, the activated receptor functions as a guanine nucleotide exchange factor (GEF), catalyzing the exchange of GDP for GTP on the G protein's α -subunit, which is the initiating step in downstream signaling.⁷

Interestingly, some T2Rs, particularly when mutated, can adopt an active conformation and signal even in the absence of an agonist.¹⁰ This phenomenon, known as basal or constitutive activity, has been observed for several T2Rs, and specific mutations creating constitutively active mutants (CAMs) have been identified.³ These CAMs are valuable experimental tools. They facilitate the study of receptor activation mechanisms and G protein coupling independent of ligand binding. Furthermore, because CAMs exhibit inherent signaling activity, they provide a convenient system for screening and characterizing compounds that reduce this activity, namely inverse agonists and antagonists (collectively often referred to as bitter blockers).³ The identification of such blockers is of significant interest for applications in taste masking for pharmaceuticals and foods.³ Studies using CAMs and site-directed mutagenesis have revealed that the same binding pocket (orthosteric site) within a T2R can often accommodate both activating agonists and inhibitory antagonists or





inverse agonists.³

The potential role of receptor oligomerization (dimerization or higher-order complexes) in T2R function has also been explored. While sweet and umami taste perception relies on obligate heterodimerization of T1R subunits (T1R2/T1R3 for sweet, T1R1/T1R3 for umami)¹³, the situation for T2Rs appears different. Studies using heterologous expression systems suggest that T2Rs can form both homodimers and heterodimers.³³ However, unlike T1Rs, T2R homodimerization does not seem to significantly alter the receptor's pharmacology (ligand specificity or potency) or its trafficking to the cell surface.³³ Some evidence suggests that heterodimerization between certain T2Rs and other GPCRs, such as the β 2-adrenergic receptor (ADR β 2) with T2R14, might occur and potentially influence receptor expression or localization, but the physiological relevance of T2R oligomerization in vivo remains largely unclear and requires further investigation in endogenous systems.³³

B. The Canonical Gustducin-Mediated Signaling Cascade

In the canonical pathway operating within taste receptor cells, T2R activation is primarily coupled to a specific heterotrimeric G protein known as gustducin.² Gustducin consists of the α -subunit Gagust (encoded by the GNAT3 gene) and the G $\beta\gamma$ dimer, typically involving G β 3 and G γ 13 subunits.² Gagust shares homology with transducin, the G protein involved in phototransduction in the retina.³⁴

Upon ligand binding and receptor conformational change, the T2R promotes the exchange of GDP for GTP on Gagust, leading to the dissociation of the activated Gagust-GTP subunit from the G $\beta\gamma$ dimer.¹ The liberated G $\beta\gamma$ subunits are the primary effectors in the main signaling branch. They directly activate the enzyme Phospholipase C β 2 (PLC β 2).²

Activated PLC β 2 catalyzes the hydrolysis of the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).¹ IP3, being water-soluble, diffuses



through the cytoplasm and binds to specific IP₃ receptors (IP₃R), which are ligand-gated Ca²⁺ channels located on the membrane of the endoplasmic reticulum (ER), the cell's internal calcium store.¹ IP₃ binding opens these channels, causing a rapid release of stored Ca²⁺ ions from the ER into the cytoplasm, leading to a significant increase in the intracellular free calcium concentration ([Ca²⁺]_i).¹

This rise in [Ca²⁺]_i serves as a crucial downstream signal, activating the Transient Receptor Potential cation channel Melastatin 5 (TRPM5).¹ TRPM5 is a Ca²⁺-activated, monovalent cation-selective channel expressed in Type II taste cells (mediating bitter, sweet, and umami). Its opening allows an influx of sodium ions (Na⁺) into the cell, leading to membrane depolarization.¹

The depolarization of the taste cell triggers the final step in signal transmission from the TRC: the release of ATP into the extracellular space of the taste bud.¹ This ATP release is mediated by specific channels, potentially including the calcium homeostasis modulator 1/3 (CALHM1/3) channel or pannexin-1 hemichannels.¹ Released ATP acts as a neurotransmitter, binding to ionotropic purinergic receptors (like P2X receptors) on the terminals of adjacent gustatory afferent nerve fibers.¹ This activation generates action potentials in the nerve, carrying the encoded bitter taste information to the central nervous system for processing and perception.¹

In addition to the primary PLCβ₂ pathway, a parallel pathway involving the dissociated Gagust subunit has been proposed.² Activated Gagust can stimulate phosphodiesterase (PDE) enzymes, which hydrolyze cyclic adenosine monophosphate (cAMP).² The resulting decrease in intracellular cAMP levels may play a modulatory role, perhaps by influencing the activity of cyclic nucleotide-gated channels or other downstream targets, although the precise contribution of this PDE pathway to the overall bitter taste response is less clearly defined than the PLCβ₂ pathway.²

While gustducin is considered the primary G protein for bitter taste, evidence from gustducin knockout mice, which retain partial sensitivity to some bitter compounds,





suggests the existence of alternative or compensatory signaling mechanisms.²⁹ Other G α subunits, such as Gai2 and Gat2 (transducin-2), are also expressed in taste cells and might couple to certain T2Rs, potentially contributing to the complexity or robustness of bitter taste signaling.²⁹ This implies a degree of signaling plasticity even within the canonical taste system, perhaps allowing for different signaling dynamics depending on the specific receptor activated or the concentration of the bitter ligand.

C. Structural and Mechanistic Distinctions from Class A GPCRs

While T2Rs belong to the GPCR superfamily, they exhibit notable structural and mechanistic differences compared to the extensively studied Class A (rhodopsin-like) GPCRs.⁶ These distinctions underscore their classification as a separate subfamily and have significant implications for understanding their function and for drug design efforts.

One key difference lies in the absence of several highly conserved amino acid motifs in T2Rs that serve as structural or functional hallmarks in Class A receptors.⁶ For example, the LXXXD motif in TM2, the (D/E)RY motif at the cytoplasmic end of TM3 (involved in G protein coupling and receptor activation), the CWXP motif in TM6 (often involved in conformational changes), and the NPXXY motif in TM7 (implicated in receptor internalization and signaling) are generally absent or poorly conserved in T2Rs.⁶

Instead, T2Rs appear to possess their own set of conserved residues and potential motifs that play crucial roles. Structure-function studies, primarily using mutagenesis and modeling of receptors like T2R1 and T2R4, have begun to shed light on these.³ For instance, a highly conserved asparagine residue at position 1.50 (using the Ballesteros-Weinstein numbering system for GPCRs; Asn-24 in T2R1) seems critical for T2R activation. Unlike its counterpart in many Class A receptors, which often stabilizes the inactive state, Asn^{1.50} in T2R1 appears to mediate an essential hydrogen bond network connecting TM1, TM2, and TM7 specifically in the agonist-bound, active state.⁶ Another conserved residue, Arg^{2.54} (Arg-55 in T2R1), part of a potential





L^{2.50}XXXR^{2.54} motif unique to T2Rs, forms an interhelical hydrogen bond with Asn^{1.50} that seems to restrain receptor activity in the basal state; disruption of this bond can lead to hyperactive receptors.⁶ Additionally, a putative LXXSL motif involving conserved residues Leu^{5.50}, Ser^{5.53}, and Leu^{5.54} at the cytoplasmic end of TM5 appears important for maintaining the structural integrity of this helix.⁶

These structural distinctions likely translate into unique activation mechanisms for T2Rs compared to Class A GPCRs.⁹ Modeling studies suggest that T2Rs may possess a less stable inactive state and undergo distinct conformational transitions upon activation.⁹ G protein coupling also appears robust, with computational models suggesting that the G protein (gustducin) interacts extensively with the receptor's cytoplasmic face, forming strong interactions, potentially including salt bridges, with residues across all three intracellular loops (ICL1, ICL2, and ICL3).⁹ These interactions likely stabilize the active receptor conformation and orient the G α subunit optimally for GTP exchange.⁹

The unique structural features and activation mechanisms of T2Rs mean that knowledge gained from Class A GPCRs cannot always be directly extrapolated. Designing pharmacological modulators – whether agonists for therapeutic purposes or antagonists/blockers for taste masking – requires specific structural insights into T2R ligand binding pockets and activation pathways.⁶ The lack of conserved Class A motifs and the presence of unique T2R features necessitate T2R-specific approaches for structure-based drug discovery.

III. Genetic Landscape of the Human T2R Family

A. Gene Repertoire: Functional Genes and Pseudogenes

The genetic basis for bitter taste perception in humans lies within the TAS2R gene family, a multigene family encoding the T2R proteins.¹ Consensus across multiple genomic analyses indicates that the human genome harbors approximately 25 functional TAS2R loci.¹ These genes encode the receptor proteins responsible for





detecting the vast array of bitter compounds.

In addition to the functional genes, the human TAS2R family includes several pseudogenes – gene copies that have lost their protein-coding ability due to mutations such as premature stop codons or frameshift insertions/deletions.²⁰ Estimates of the number of TAS2R pseudogenes in humans typically range from 7 to 11.² Some of these pseudogenization events appear to be lineage-specific, occurring after the divergence of humans from other primates (e.g., hTAS2R62, hTAS2R64).²⁰ Others, like hTAS2R2, exhibit polymorphic inactivation, meaning both functional and non-functional alleles exist within the human population.²⁵ The co-existence of a significant number of functional genes alongside multiple pseudogenes is a hallmark of gene families undergoing dynamic evolution. This pattern reflects a history of gene duplication events (birth), which create new gene copies, followed by either functional divergence or, frequently, loss of function through mutation accumulation (death).² This "birth-and-death" evolutionary model suggests that the T2R repertoire is not static but is continuously shaped by selective pressures, likely related to changes in diet and exposure to environmental toxins over evolutionary time.

Compared to other sensory GPCR families, the size of the human T2R family (~25 functional genes) is intermediate. It is considerably larger than the family of opsins responsible for vision (typically 4 functional genes) but much smaller than the olfactory receptor (OR) family, which comprises hundreds of functional genes in humans.² This intermediate size likely reflects a balance between the need to detect a wide variety of potentially harmful bitter compounds and the evolutionary constraints on maintaining such a large gene family.

B. Genomic Organization and Structural Features

The human TAS2R genes are not randomly scattered throughout the genome but are primarily organized into clusters located on specific chromosomes.¹ The major clusters are found on:

- Chromosome 5: Specifically at locus 5p15, containing the single gene TAS2R1.¹





- Chromosome 7: A large cluster resides at 7q31-q35, harboring numerous TAS2R genes, including the well-studied TAS2R38, as well as TAS2R3, TAS2R4, TAS2R5, TAS2R16, and others.¹
- Chromosome 12: Another significant cluster is located at 12p13, containing genes such as TAS2R7, TAS2R8, TAS2R9, TAS2R10, TAS2R13, TAS2R14, and several others.¹

This clustered arrangement, often featuring genes in tandem arrays, is characteristic of multigene families that have expanded through local gene duplication events.²¹ Such organization facilitates further duplication or deletion via mechanisms like unequal crossing-over during meiosis, contributing to the evolutionary plasticity and size variation observed in the T2R family across different species.

As mentioned previously, a key structural feature at the gene level is the lack of introns within the protein-coding regions of TAS2R genes.² The entire coding sequence, typically around 900-1000 base pairs, is contained within a single exon.² This genetic simplicity further facilitates gene duplication and potentially allows for rapid evolution and adaptation of the bitter taste repertoire.

C. Polymorphisms, Haplotypes, and Variations in Bitter Taste Sensitivity

The human TAS2R gene family is characterized by extensive genetic variation within and between populations.¹ This variation takes multiple forms, including:

- **Single Nucleotide Polymorphisms (SNPs):** The most common type of variation, involving changes at single base positions. A large-scale analysis identified hundreds of SNPs across the 25 functional TAS2R genes, with a significant proportion (over 400) being nonsynonymous, meaning they result in an amino acid change in the encoded receptor protein.⁵⁶ These nonsynonymous SNPs are prime candidates for altering receptor function.¹⁵
- **Insertions/Deletions (Indels):** Variations involving the insertion or deletion of one or more nucleotides. These can cause frameshifts if they occur within the coding region and are not multiples of three, often leading to non-functional





proteins.⁵⁶

- **Copy Number Variations (CNVs):** Variations in the number of copies of a particular gene or gene segment. Some TAS2R genes, like TAS2R43 and TAS2R45, are known to have relatively high-frequency whole-gene deletion alleles in human populations.²⁵

This rich tapestry of genetic variation is the primary molecular basis for the well-documented individual differences in bitter taste perception and sensitivity observed in humans.² Specific polymorphisms, often occurring together on the same chromosome as haplotypes, can significantly alter the receptor's ability to bind and respond to certain bitter ligands.

The most extensively studied example is the TAS2R38 gene.³ Three common nonsynonymous SNPs at codon positions 49 (Proline/Alanine, rs713598), 262 (Alanine/Valine, rs1726866), and 296 (Valine/Isoleucine, rs10246939) are in high linkage disequilibrium and define two major haplotypes worldwide:

- **PAV (Proline-Alanine-Valine):** The "taster" haplotype, associated with high sensitivity to thiourea compounds like phenylthiocarbamide (PTC) and 6-n-propylthiouracil (PROP).⁵⁸
- **AVI (Alanine-Valine-Isoleucine):** The "non-taster" haplotype, associated with significantly reduced or absent sensitivity to PTC/PROP.⁵⁸

Individuals homozygous for PAV (PAV/PAV) are typically sensitive tasters ("supertasters" or medium tasters), those homozygous for AVI (AVI/AVI) are non-tasters, and heterozygotes (PAV/AVI) usually exhibit intermediate sensitivity.⁸⁰ These TAS2R38 genotypes account for a large proportion (up to 85%) of the variation in PTC/PROP taste perception.⁸⁰ Rarer haplotypes (e.g., AAV, AAI, PVI, PAI) also exist and can confer intermediate sensitivity levels, contributing to the continuous range of bitter perception phenotypes observed rather than strictly distinct categories.⁸⁰

Polymorphisms in other TAS2R genes have also been linked to sensitivity variations for





different bitter compounds. For example:

- TAS2R16 variants influence sensitivity to β -glucopyranosides like salicin.⁴⁰
- TAS2R43 and TAS2R44 variants affect sensitivity to the artificial sweeteners saccharin and acesulfame K.⁵⁶
- TAS2R14 polymorphisms may influence responses to compounds like aristolochic acid or quinine, although associations with perception phenotypes are less clear.⁵⁹
- Variations in the TAS2R30/31/43/45/46 cluster are associated with sensitivity to various synthetic sweeteners and phytotoxins.⁵⁸
- Polymorphisms in TAS2R9 and TAS2R31 influence sensitivity to specific phytotoxins.⁸⁶
- Genetic variation across the TAS2R cluster on chromosome 12 has been associated with caffeine and quinine perception.¹⁰³

The extensive polymorphism across the TAS2R family provides a powerful molecular explanation for individual differences in taste worlds. This variation has profound implications, potentially influencing food choices (e.g., avoidance of bitter vegetables like Brassicas, which contain TAS2R38 ligands⁵⁶), dietary patterns, acceptance of bitter medicines (affecting compliance)³, and even susceptibility to certain health conditions linked either to diet or to the extraoral functions of T2Rs.² This genetic variability forms the basis for potential applications in personalized nutrition and medicine, where genotype information could predict individual responses and guide interventions. However, while TAS2R38 provides a relatively straightforward example, predicting sensitivity to the vast array of other bitter compounds is more complex. It likely involves the interplay of multiple T2Rs and the combined effects of polymorphisms across several genes, necessitating analyses that consider the entire functional TAS2R repertoire and haplotype structures.²⁶

Table 1: Overview of the Human TAS2R Gene Family



plantrica

Gene Name	Chromosomal Location	Status	Key Polymorphisms / Notes	Example Ligands
TAS2R1	5p15	Functional		
TAS2R2	7q34	Pseudogene (Polymorphic)	Human-specific pseudogenization (polymorphic deletion) ²⁵	Ancestral receptor likely functional ²⁵
TAS2R3	7q34	Functional		Chloroquine, Denatonium ¹⁰⁶
TAS2R4	7q34	Functional		Quinine, Denatonium ³ ; Inhibited by GABA, BCML ³
TAS2R5	7q34	Functional		
TAS2R7	12p13	Functional		Strychnine, Quinacrine, Chloroquine, Papaverine ⁵⁰
TAS2R8	12p13	Functional		Denatonium ¹⁰⁶
TAS2R9	12p13	Functional	Polymorphisms affect sensitivity	



plantrica

			86	
TAS2R10	12p13	Functional	Broadly tuned ⁵⁷	Strychnine, Denatonium, Chloroquine ⁵⁷
TAS2R13	12p13	Functional		
TAS2R14	12p13	Functional	Very broadly tuned (>150 ligands) ¹⁶	Aristolochic acid, Diphenhydramin e, Apigenin, Flufenamic acid, Quinine ¹⁶
TAS2R16	7q34	Functional	Broadly tuned for β -glucopyranosi des ⁵⁷	Salicin, Arbutin ⁴⁰
TAS2R18	12p13	Pseudogene	Human-specific stop codon ⁵⁴	
TAS2R19	12p13	Functional		
TAS2R20	12p13	Functional		
TAS2R30	7q35	Functional	Part of polymorphic cluster ⁵⁸	



plantrica

TAS2R31	7q35	Functional	Part of polymorphic cluster; affects sweetener bitterness ⁵⁸	Saccharin, Acesulfame K ⁵⁶
TAS2R38	7q34	Functional	PAV (taster) / AVI (non-taster) haplotypes ⁸⁰	PTC, PROP, Goitrin, Isothiocyanates, Bacterial AHLs ⁴⁶
TAS2R39	7q34	Functional	Broadly tuned ⁵⁷	Apigenin ⁷⁴
TAS2R40	7q34	Functional	Inhibited by GIV3727 ¹⁰⁰	Diphenhydramine ⁹²
TAS2R41	7q34	Functional	Orphan receptor ⁶⁰	
TAS2R42	12p13	Functional	Orphan receptor ⁶⁰	
TAS2R43	12p13	Functional	High frequency deletion allele; affects sweetener bitterness ⁵⁶	Saccharin, Acesulfame K ⁵⁶ ; Inhibited by GIV3727 ¹⁰⁰
TAS2R44	12p13	Functional	Affects sweetener bitterness ⁵⁶	Saccharin, Denatonium, 6-Nitrosacchari



plantrica

				n ⁵⁶
TAS2R45	12p13	Functional	High frequency deletion allele; Part of polymorphic cluster ⁵⁶	
TAS2R46	12p13	Functional	Broadly tuned; Part of polymorphic cluster ⁵⁷	Strychnine; Inhibited by sesquiterpene lactones ⁷²
TAS2R48	12p13	Functional	Orphan receptor ⁶⁰	
TAS2R49	12p13	Functional		
TAS2R50	12p13	Functional		
TAS2R55	12p13	Functional		
TAS2R60	12p13	Functional	Orphan receptor ⁶⁰	
TAS2R62	7q34	Pseudogene	Human-specific fixed nonsense mutations ²⁵	Ancestral receptor likely functional ²⁵
TAS2R64	7q34	Pseudogene	Human-specific fixed nonsense	Ancestral receptor likely



plantrica

			mutation ²⁵	functional ²⁵
Other Ps	7, 12	Pseudogene	Various pseudogenes exist ²¹	

Note: This table synthesizes information from multiple sources. Ligand lists are examples and not exhaustive. Orphan status may change with further research. Pseudogene counts vary slightly between studies. ²

IV. Beyond the Tongue: Extraoral T2R Expression and Functions

A. Widespread Distribution

While initially characterized as mediators of bitter taste in the oral cavity, a paradigm shift has occurred over the past two decades with the discovery that T2Rs and their associated signaling molecules (such as Gα-gustducin, PLCβ2, and TRPM5) are expressed in a surprisingly wide array of tissues and cell types outside the gustatory system.¹ This extraoral expression suggests that T2Rs play diverse physiological roles beyond taste perception, acting as chemosensors in various internal environments.

Key locations where extraoral T2R expression has been documented include:

- **Respiratory System:** T2Rs are found throughout the respiratory tract, from the nasal cavity and sinuses down to the bronchioles. Specific cell types expressing T2Rs include airway smooth muscle (ASM) cells, ciliated epithelial cells (where receptors are often localized to the motile cilia), specialized chemosensory cells like solitary chemosensory cells (SCCs), brush cells, and tuft cells, as well as various resident and recruited immune cells such as macrophages, mast cells, lymphocytes, and neutrophils.¹
- **Gastrointestinal (GI) System:** Expression is documented along the GI tract, including the stomach, small intestine (duodenum, jejunum, ileum), and large





intestine. T2Rs are notably present in specialized hormone-secreting enteroendocrine cells (EECs), such as those producing GLP-1, CCK, and ghrelin, as well as in gut tuft cells and pancreatic cells.¹

- **Cardiovascular System:** T2R transcripts and proteins have been detected in cardiac myocytes within the heart and in cells of the vasculature, including vascular smooth muscle and endothelial cells.¹
- **Nervous System:** Expression has been reported in various brain regions, including the brainstem and choroid plexus, as well as potentially on sensory nerve fibers that interact with chemosensory cells in peripheral tissues.¹
- **Immune System:** T2Rs are expressed by various circulating and tissue-resident immune cells, including lymphocytes, monocytes, macrophages, granulocytes, leukocytes, and mast cells, suggesting roles in immune surveillance and modulation.¹
- **Other Tissues:** The list of tissues with reported T2R expression continues to grow and includes the male reproductive system (testis, relevant to spermatogenesis), the urinary system (bladder, urethra), the integumentary system (skin keratinocytes), the skeletal system (osteoclasts, osteocytes), endocrine glands (thyroid), metabolic tissues (adipose tissue, liver), and the female reproductive system (endometrium, placenta).¹

It is important to note that the expression levels of different T2R subtypes can vary considerably between tissues, and not all 25 functional human T2Rs are necessarily expressed in every location.³³ Some T2Rs appear to be broadly expressed, while others exhibit more restricted tissue distribution.³³ This differential expression likely reflects specialized roles for specific T2R subtypes in different physiological contexts.

B. Diverse Extraoral Signaling Pathways and Physiological Roles

The activation of extraoral T2Rs triggers intracellular signaling cascades that initiate diverse physiological responses tailored to the specific cell type and tissue context.¹ While the initial steps often mirror the canonical taste pathway – involving ligand binding, G protein (often gustducin or related Gai/o proteins) activation, PLCβ2





stimulation, and a subsequent rise in intracellular calcium ($[Ca^{2+}]_i$) – the downstream consequences diverge significantly.¹ These divergent pathways can be broadly categorized into cell-autonomous, paracrine, and endocrine mechanisms, leading to a wide range of non-gustatory functions.

1. Cell-Autonomous Regulation: In this mode, the effects of T2R activation are largely confined to the cell expressing the receptor.

- **Airway Ciliary Function:** In ciliated epithelial cells lining the airways, T2R activation by bitter compounds (including bacterial products like AHLs detected by T2R38) leads to an increase in $[Ca^{2+}]_i$.¹ This Ca^{2+} signal stimulates the production of nitric oxide (NO) via endothelial nitric oxide synthase (eNOS).¹⁶ NO, in turn, likely activates protein kinase G (PKG) signaling pathways that increase ciliary beat frequency (CBF).⁹² This enhancement of CBF accelerates mucociliary clearance, a critical innate defense mechanism for removing trapped pathogens and irritants from the airways.¹ The heat shock protein HSP90 appears to be a crucial component facilitating the coupling between T2R signaling and eNOS activation in these cells.⁹⁸ Additionally, the NO produced can diffuse into the airway surface liquid and exert direct antimicrobial effects, particularly against gram-negative bacteria like *Pseudomonas aeruginosa*.¹⁶
- **Airway Smooth Muscle (ASM) Relaxation:** Perhaps one of the most striking extraoral functions is the potent relaxation of pre-contracted airway smooth muscle induced by T2R agonists.¹ While T2R activation in ASM also causes an initial rise in $[Ca^{2+}]_i$, the downstream effect leading to relaxation is complex and distinct from simple Ca^{2+} -triggered contraction.¹ Current evidence suggests that the $G\beta\gamma$ subunits dissociated from the activated G protein (potentially gustducin or other $G_{ai/o}$ proteins) play a key role by inhibiting L-type voltage-dependent Ca^{2+} channels.¹ This inhibition reduces Ca^{2+} influx, counteracting the elevated $[Ca^{2+}]_i$ induced by bronchoconstrictors and leading to muscle relaxation.¹ Early hypotheses involving the activation of large-conductance Ca^{2+} -activated K^+ (BKCa) channels have been largely refuted or questioned.¹ Furthermore, T2R activation in ASM has been shown to inhibit cell proliferation, suggesting a





potential role in mitigating airway remodeling, a key feature of chronic asthma and COPD.¹¹⁴

2. Paracrine Regulation: Here, T2R activation causes the release of signaling molecules that act locally on neighboring cells.

- **Gastrointestinal Tract:** In specialized enteroendocrine cells (EECs) of the small intestine, T2R stimulation triggers the release of the peptide hormone cholecystikinin (CCK).¹ CCK can then act via CCK2 receptors on adjacent enterocytes to upregulate the activity of the efflux pump ABCB1 (also known as P-glycoprotein or MDR1), which actively transports toxins (including bitter ones) out of the cells and back into the gut lumen.¹ Alternatively, CCK can activate CCK1 receptors on vagal afferent nerve endings, sending satiety signals to the brain to help regulate food intake.¹
- **Airways and Nasal Cavity:** Solitary chemosensory cells (SCCs) or brush cells in the nasal cavity, vomeronasal organ, and trachea respond to bitter compounds or bacterial signals by releasing acetylcholine (ACh).¹ This ACh acts on nicotinic receptors on nearby sensory nerve fibers, triggering protective reflexes such as decreased breathing rate, sneezing, coughing, or neurogenic inflammation.¹ Additionally, SCCs in the upper airway can release antimicrobial peptides (AMPs) like β -defensins upon T2R stimulation, contributing directly to local innate immunity.⁴⁷ This AMP release is interestingly suppressed by activation of sweet taste receptors (T1R2/T1R3) on the same cells, suggesting a mechanism to conserve resources during health and fully deploy defenses during infection when glucose levels (activating T1Rs) might be lowered by bacteria.¹²²
- **Gut Immunity (Tuft Cells):** Intestinal tuft cells, another type of chemosensory cell, express T2Rs (and T1Rs) and play a critical role in orchestrating immune responses against parasitic infections (e.g., helminths).¹ Upon detecting parasite-derived molecules (potentially bitter), these cells release the cytokine interleukin-25 (IL-25). IL-25 activates type 2 innate lymphoid cells (ILC2s), leading to the production of type 2 cytokines (like IL-4, IL-5, IL-13) that promote parasite expulsion and also induce the proliferation (hyperplasia) of the tuft cells





themselves, creating a positive feedback loop to amplify the defense response.¹

- **Urinary Tract:** A similar reflex involving ACh release from urethral brush cells upon bitter stimulation triggers bladder smooth muscle contraction and urination, potentially serving to flush out irritants or pathogens.¹

3. Endocrine Regulation: In this mechanism, T2R activation leads to the release of hormones that enter the bloodstream and act systemically on distant target organs.

- **Glucose Homeostasis:** T2R activation in gut EECs (specifically L-cells) stimulates the secretion of glucagon-like peptide-1 (GLP-1).¹ GLP-1 is an incretin hormone that travels via the circulation to the pancreas, where it potentiates glucose-stimulated insulin secretion from β -cells, thereby helping to lower blood glucose levels after a meal.¹ This links bitter sensing in the gut directly to systemic metabolic regulation.
- **Appetite Regulation:** Activation of T2Rs in ghrelin-producing cells in the stomach can stimulate the release of ghrelin, the "hunger hormone," which can paradoxically increase short-term food intake and accelerate gastric emptying.⁴⁹ However, bitter compounds can also exert direct inhibitory effects on gastric contractility and delay gastric emptying, leading to a subsequent prolonged decrease in food intake.⁴⁹ The net effect on appetite appears complex and may depend on the specific bitter compound and context.

4. Immune System Modulation: Beyond the localized innate defenses in epithelia, T2Rs expressed directly on various immune cells modulate their activity. Activation of T2Rs on macrophages, for example, can enhance phagocytosis via NO/cGMP signaling.¹⁶ T2R stimulation on mast cells, lymphocytes, monocytes, and other leukocytes can suppress the release of pro-inflammatory cytokines (e.g., TNF- α , IL-1 β , IL-2, IL-4, IL-5) and other inflammatory mediators like histamine.¹⁴ This suggests a broad anti-inflammatory role for T2Rs in systemic immunity.

5. Other Potential Functions: Emerging evidence points to roles for extraoral T2Rs in other systems. In the cardiovascular system, they may influence cardiac contractility





and vascular smooth muscle tone.³³ In bone, T2R38 expressed on osteoclasts can detect bacterial quorum-sensing molecules, potentially linking infection to bone inflammation, and T2R signaling might influence bone formation and resorption via calcium modulation.¹⁰⁴ Roles in reproduction (spermatogenesis)¹ and the regulation of apoptosis in both normal and cancerous cells are also under investigation.¹⁶

The discovery of this widespread extraoral expression and the diverse array of functions firmly establishes T2Rs as more than just taste receptors. They function as a distributed chemosensory network, acting as sentinels that monitor the internal environment for a variety of chemical cues – including dietary components, microbial products, potential toxins, and perhaps endogenous metabolites or pharmaceuticals.¹ The ability of the same initial Ca²⁺ signal to elicit different, context-dependent responses underscores the sophistication of this system and the importance of the downstream cellular machinery in interpreting the T2R signal.¹ Furthermore, the fact that many existing pharmaceutical drugs are bitter and can activate T2Rs provides a compelling explanation for some previously poorly understood off-target drug effects and highlights the importance of considering T2R interactions during drug development.³

Table 2: Summary of Extraoral T2R Expression and Key Functions

Tissue/System	Cell Type(s)	Key T2R Subtypes (Examples)	Primary Ligands/Stimuli (Examples)	Key Signaling Effectors/Mechanisms	Major Physiological Function(s)	Supporting Snippets (Examples)
Respiratory System	Ciliated Epithelial Cells	T2R4, T2R14, T2R16,	Bitter compounds,	Ca ²⁺ , eNOS → NO, PKG	Mucociliary clearance,	¹



plantrica

		T2R38, T2R46	Bacterial AHLs & Quinolone s (T2R38)	-> ↑CBF	Innate defense (bacterici dal NO)	
	Airway Smooth Muscle (ASM)	T2R4, T2R10, T2R14, T2R107 (mouse)	Bitter agonists (Quinine, Chloroqui ne, Denatoniu m)	Ca ²⁺ increase -> Gβγ -> Inhibition of L-type Ca ²⁺ channels -> ↓[Ca ²⁺] _i	Bronchodi lation, Relaxation , Anti-prolif eration (remodelin g)	¹
	Solitary Chemosen sory Cells (SCCs) / Brush Cells	T2Rs (general), T1Rs	Bitter compound s, Bacterial products	Ca ²⁺ -> ACh release -> Nerve activation; Ca ²⁺ wave -> AMP release (inhibited by T1R)	Protective reflexes (cough, sneeze, inflammati on), Antimicro bial peptide secretion	¹
Gastroint estinal (GI) System	Enteroend ocrine Cells (EECs - L-cells, Ghrelin cells, etc.)	T2Rs (multiple)	Bitter compound s, Nutrients	Ca ²⁺ -> CCK release; Ca ²⁺ -> GLP-1 release; Ca ²⁺ -> Ghrelin	Appetite regulation (via CCK, Ghrelin), Glucose homeosta sis (via GLP-1 -> insulin),	¹



plantrica

				release	Toxin efflux (via CCK->AB CB1)	
	Gut Tuft Cells	T2Rs, T1Rs	Parasite metabolites?	Ca ²⁺ -> IL-25 release	Orchestration of Type 2 immunity against parasites	¹
	Stomach/Intestine (general)	T2Rs (multiple)	Bitter compounds, Toxins	Delayed gastric emptying, Increased motility/secretion	Protective reflexes (vomiting, diarrhea), Nutrient sensing	⁴²
Immune System	Macrophages, Monocytes, Mast cells, Lymphocytes, Neutrophils	T2Rs (various)	Bitter compounds, Bacterial products	Ca ²⁺ -> NO/cGMP -> ↑Phagocytosis; Suppression of pro-inflammatory cytokines (TNFα, ILs), Histamine release	Innate immunity modulation, Anti-inflammatory effects	¹



plantrica

Cardiovascular System	Cardiac Myocytes, Vascular Smooth Muscle/Endothelium	T2R14, T2R20 (high in heart); others moderate/low	Bitter compounds	Ca ²⁺ signaling	Regulation of cardiac contractility, Vascular tone (relaxation)	33
Nervous System	Brain (various regions), Sensory Nerves	T2Rs (various)	Bitter compounds? Endogenous ligands?	Potential Ca ²⁺ signaling	Regulation of food intake?, Neuroinflammation?, Unknown functions	1
Skeletal System	Osteoclasts, Osteocytes	T2R38	Bacterial quorum-sensing molecules	Ca ²⁺ signaling	Bone inflammation modulation, Potential role in bone remodeling	104
Urinary System	Urethral Brush Cells, Bladder	T2Rs	Bitter compounds	Ca ²⁺ → ACh release → Bladder contraction	Urination reflex, Flushing of irritants/pathogens	1



Reproductive System	Testis (Spermatozoa)	T2R5 (mouse)	Unknown	Unknown	Spermatogenesis	¹
Integumentary System	Skin Keratinocytes	T2Rs	Bitter compounds	Ca ²⁺ -> ABCB1 upregulation?	Toxin excretion? Barrier function?	¹⁴
Cancer Cells	Various (HNSCC, Pancreatic, Breast, etc.)	T2R10, T2R14, T2R38, T2R42	Bitter compounds, Bacterial metabolites	Nuclear Ca ²⁺ -> Mitochondrial depolarization -> Caspase activation	Apoptosis induction, Chemoresistance modulation (MDR)	¹⁶

Note: This table provides examples and summarizes key findings; T2R subtype expression and specific functions are areas of active research and may be more complex. CBF = Ciliary Beat Frequency; AHL = Acyl-Homoserine Lactone; NO = Nitric Oxide; eNOS = endothelial NO Synthase; PKG = Protein Kinase G; ASM = Airway Smooth Muscle; SCC = Solitary Chemosensory Cell; AMP = Antimicrobial Peptide; EEC = Enteroendocrine Cell; CCK = Cholecystokinin; GLP-1 = Glucagon-Like Peptide-1; ABCB1 = ATP Binding Cassette Subfamily B Member 1 (MDR1); ACh = Acetylcholine; IL = Interleukin.

V. The Chemical World of T2R Ligands

A. Ligand Diversity

A defining characteristic of the T2R family is its ability to recognize an exceptionally broad and chemically diverse spectrum of ligands.³ This chemical promiscuity is





fundamental to the receptors' role in detecting potentially harmful substances from various sources. The known agonists for T2Rs encompass several major categories:

- **Natural Plant Toxins and Secondary Metabolites:** This is perhaps the most recognized category, reflecting the evolutionary pressure to avoid poisonous plants. T2Rs are activated by numerous plant-derived compounds, including alkaloids (e.g., quinine from *Cinchona* bark, strychnine from *Strychnos nux-vomica*, nicotine from tobacco, caffeine from coffee/tea, papaverine from opium poppy), various terpenoids and sesquiterpene lactones (e.g., andrographolide from *Andrographis paniculata*, parthenolide from feverfew), glycosides (e.g., salicin from willow bark, amygdalin from bitter almonds, numerous β -glucopyranosides, cyanogenic glycosides), flavonoids (e.g., naringin from grapefruit, apigenin found in chamomile and other plants), polyphenols (like epigallocatechin gallate from green tea), peptides, and amines.³ Many of these compounds serve as defense chemicals for the plants.¹⁶
- **Pharmaceuticals and Drugs:** A significant number of commonly used drugs elicit a bitter taste, and many have been experimentally confirmed as T2R agonists.³ Examples span various therapeutic classes: antimalarials (quinine, chloroquine³), antibiotics (erythromycin, ofloxacin, chloramphenicol, tobramycin³), antihistamines (diphenhydramine¹⁶), antipsychotics (haloperidol¹¹⁰), antiarrhythmics (procainamide¹¹⁰), non-steroidal anti-inflammatory drugs (flufenamic acid¹⁶), microtubule inhibitors used in chemotherapy (colchicine¹⁶), local anesthetics (lidocaine¹⁶), and others.³ This overlap has significant implications for drug palatability and potential off-target effects mediated by extraoral T2Rs.
- **Synthetic Compounds:** Many synthetic chemicals are perceived as bitter and activate T2Rs. These include intensely bitter compounds used as aversives, like denatonium benzoate (Bitrex) and denatonium saccharide¹⁵, as well as artificial sweeteners that possess bitter off-tastes, such as saccharin and acesulfame K.⁴⁰ Derivatives like 6-nitrosaccharin have also been identified as T2R agonists.¹⁰⁵
- **Bacterial Metabolites:** A crucial discovery linking T2Rs to innate immunity is their





ability to detect molecules secreted by bacteria, particularly gram-negative species.¹⁴ These include quorum-sensing molecules, such as acyl-homoserine lactones (AHLs) like N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12HSL) produced by *Pseudomonas aeruginosa*, which are detected by receptors like T2R38.¹⁶ Bacterial quinolones are another class of metabolites recognized by T2Rs.¹⁶ This ability allows extraoral T2Rs, particularly in the airways, to function as sentinels for bacterial presence and virulence.

- **Potential Endogenous Ligands:** While T2Rs primarily evolved to detect exogenous substances, there is emerging, though still debated, evidence that some T2Rs might respond to endogenous molecules. Studies in fish suggest activation by steroid hormones and bile acids.²⁸ In humans, the inhibitory neurotransmitter γ -aminobutyric acid (GABA) has been identified as an antagonist for T2R4, representing a potential endogenous modulator.³ The existence and physiological relevance of true endogenous T2R agonists in mammals remain areas of active investigation.¹¹²

The sheer chemical diversity of T2R ligands highlights the receptors' role as broad-spectrum detectors of potentially harmful or biologically relevant molecules from the diet, the environment, resident microbiota, and even potentially from within the body itself.

B. Receptor Specificity and Tuning Breadth

While the T2R family collectively recognizes a vast chemical space, individual T2R subtypes exhibit significant variation in their ligand specificity, a property referred to as "tuning breadth".³ This variation ranges from highly selective receptors to extremely promiscuous ones:

- **Narrowly Tuned ("Specialists"):** Some T2Rs are activated by only one or a very limited set of structurally related compounds. Classic examples include mouse T2R5, which is specifically activated by the protein synthesis inhibitor cycloheximide¹⁵, and human TAS2R38, which primarily recognizes compounds containing the thiourea (N-C=S) moiety, such as PTC, PROP, and goitrin.⁵⁷ Human





TAS2R3 is also considered relatively selective.⁷⁵

- **Broadly Tuned ("Generalists" / "Promiscuous"):** Other T2Rs display remarkable promiscuity, responding to dozens or even hundreds of chemically diverse agonists.³ Notable human examples include TAS2R14, often cited as the most broadly tuned human T2R with over 170 known agonists spanning numerous chemical classes.¹⁶ Other broadly tuned human receptors include TAS2R7, TAS2R10, TAS2R16, TAS2R39, TAS2R43, TAS2R46, and TAS2R47.³ Together, just three broadly tuned receptors (hTAS2R10, hTAS2R14, hTAS2R46) were found to detect approximately 50% of a large panel of tested bitter compounds.⁵⁷
- **Moderately Tuned:** Many T2Rs fall between these extremes, recognizing several distinct chemical structures but not exhibiting the extreme promiscuity of the generalists.

This strategy of employing a mix of specialist and generalist receptors allows the relatively small T2R repertoire (~25 functional genes in humans) to effectively monitor the vast chemical landscape of potential bitter substances, estimated to be in the tens of thousands.²⁶ The system relies on combinatorial coding: a single bitter compound often activates multiple T2R subtypes²⁶, and a single T2R-expressing taste cell likely expresses multiple T2R subtypes.¹⁵ The overall pattern of receptor activation across the T2R repertoire encodes information about the bitter stimulus, although the perception is generally a uniform sensation of bitterness. Despite extensive screening efforts, several human T2Rs (e.g., TAS2R41, TAS2R42, TAS2R45, TAS2R48, TAS2R60) remain "orphan" receptors, meaning no activating ligands have yet been identified.³⁹

The broad tuning of many T2Rs, particularly receptors like T2R14, coupled with their widespread extraoral expression, creates a high probability for interactions with pharmaceutical compounds.¹⁶ This inherent promiscuity means that drugs targeting other pathways but possessing bitter properties might inadvertently activate extraoral T2Rs, leading to off-target effects.³ While this can be problematic, causing unwanted side effects, it also opens possibilities for drug repurposing if the activation of an extraoral T2R pathway proves beneficial for a particular condition. Furthermore, the





detection of bacterial metabolites like AHLs by specific T2Rs (e.g., T2R38) provides a direct mechanism for interkingdom communication, enabling the host immune system to sense bacterial presence and coordinate defenses.¹⁴

C. Bitter Blockers and Taste Masking Strategies

The intensely bitter taste of many essential medicines poses a significant challenge to patient compliance, particularly for pediatric and geriatric populations who often rely on liquid formulations where bitterness is difficult to conceal.³ Similarly, undesirable bitterness in certain healthy foods (e.g., some vegetables, soy products) or functional food ingredients can limit consumer acceptance.¹²⁵ Consequently, there is considerable interest in developing strategies to mask or block bitter taste in both the pharmaceutical and food industries.³

Traditional taste masking approaches often rely on physical methods or flavor modification:

- **Flavor/Sweetener Addition:** Using strong flavors or high-intensity sweeteners (like sucralose, aspartame) to overpower or distract from the bitterness.⁷⁶ Cooling agents like menthol can also numb taste perception.¹³⁰
- **Physical Encapsulation/Coating:** Creating a physical barrier between the bitter compound and taste receptors using techniques like microencapsulation, polymer coating, or granulation.⁷⁶ The coating must dissolve later in the GI tract to release the active ingredient.¹³⁰
- **Complexation:** Using agents like cyclodextrins to form inclusion complexes that sequester the bitter molecule, reducing its availability to bind receptors.¹⁰¹
- **Matrix Entrapment:** Incorporating the bitter drug into a matrix (polymeric, lipid-based) that slows its dissolution in saliva.⁷⁶
- **Prodrug/Salt Formation:** Chemically modifying the drug into an inactive prodrug or a less soluble salt form that has reduced bitterness, relying on subsequent biotransformation or dissolution to release the active drug.¹³⁰

An alternative and potentially more targeted approach involves identifying specific





molecules – **bitter blockers** – that directly interfere with T2R function at the receptor level.³ These blockers can act as:

- **Antagonists:** Bind to the receptor (often at the same orthosteric site as agonists) but do not activate it, thereby competitively inhibiting agonist binding.³
- **Inverse Agonists:** Bind to the receptor and stabilize it in an inactive conformation, reducing even basal (agonist-independent) activity.³

Despite the potential advantages of receptor-targeted blockers, relatively few have been definitively characterized.³ Known examples include:

- **GIV3727 (4-(2,2,3-trimethylcyclopentyl)butanoic acid):** A synthetic antagonist effective against several T2Rs, including T2R40 and T2R43.³
- **GABA (γ -aminobutyric acid):** The inhibitory neurotransmitter acts as an antagonist specifically at T2R4.³
- **BCML (N-(2-((1H-benzo[d]imidazol-2-yl)thio)ethyl)-4-methylbenzenesulfonamide):** Identified as an inverse agonist for T2R4.³
- **Sesquiterpene Lactones:** Certain natural compounds like 3 β -hydroxydihydrocostunolide from wormwood can antagonize specific receptors, such as T2R46.⁷²
- **Adenosine 5'-monophosphate (AMP), Sodium Gluconate, Sodium Acetate:** These compounds are generally regarded as safe (GRAS) and have shown bitter blocking activity in human sensory panels and nerve response studies, potentially acting at the receptor or downstream signaling level.¹⁰¹
- **Other potential modulators:** Various peptides, amino acid derivatives (e.g., l-ornithyl- β -alanine), fatty acids (oleic acid), and phospholipids (phosphatidic acid) have demonstrated bitterness reduction, although their precise mechanisms (receptor interaction vs. physical complexation) require further elucidation.³

Developing effective bitter blockers faces challenges. Because many bitter drugs activate multiple T2Rs, a blocker targeting only one receptor may only partially reduce the overall bitterness.¹⁰¹ Finding broad-spectrum blockers or using combinations of



specific blockers might be necessary.¹⁰¹ Furthermore, given the widespread physiological roles of extraoral T2Rs, systemic absorption of potent blockers could lead to unintended side effects by interfering with these functions. Therefore, the ideal blocker might be one that acts locally in the oral cavity without significant systemic absorption, or one whose blocking action is highly specific to the T2Rs activated by the target drug or food component. The search for safe and effective bitter blockers remains an active area of research in both food science and pharmaceutical development.

Table 3: Examples of T2R Ligands and Associated Receptors

Ligand Category	Specific Ligand Example	Known Human T2R(s) Activated (+) / Inhibited (-)	Primary Source/Use	Supporting Snippets (Examples)
Plant Alkaloid	Quinine	(+) T2R4, T2R7, T2R10, T2R14, T2R39, T2R40, T2R43, T2R44, T2R46	Cinchona Bark / Antimalarial, Bitterant	³
Plant Alkaloid	Strychnine	(+) T2R7, T2R10, T2R46	<i>Strychnos nux-vomica</i> / Poison	⁴⁷
Plant Alkaloid	Caffeine	(+) T2R7, T2R10, T2R14, T2R43, T2R46	Coffee, Tea / Stimulant	³



plantrica

Plant Glycoside	Salicin	(+) T2R16	Willow Bark / Precursor to Aspirin	40
Plant Flavonoid	Apigenin	(+) T2R14, T2R39	Chamomile, Parsley / Nutraceutical	16
Plant Sesquiterpene Lactone	Parthenolide	(+) T2Rs (various)	Feverfew / Potential anti-inflammatory	16
Synthetic Bitterant	Denatonium Benzoate	(+) T2R3, T2R4, T2R8, T2R10, T2R16, T2R38, T2R43, T2R44, T2R47	Synthetic / Aversive agent	15
Synthetic Sweetener (Bitter Off-Taste)	Saccharin	(+) T2R31, T2R43, T2R44	Synthetic / Artificial sweetener	56
Synthetic Compound	6-Nitrosaccharin	(+) T2R44, T2R61	Synthetic	105
Pharmaceutical (Antimalarial)	Chloroquine	(+) T2R3, T2R7, T2R10, T2R14, T2R38, T2R40	Synthetic / Antimalarial, Anti-inflammatory	3
Pharmaceutical (Antibiotic)	Erythromycin	(+) T2Rs (various)	Bacterial fermentation /	3



plantrica

			Antibiotic	
Pharmaceutical (Antibiotic)	Ofloxacin	(+) T2Rs (various)	Synthetic / Antibiotic	3
Pharmaceutical (Antihistamine)	Diphenhydramine	(+) T2R14, T2R40	Synthetic / Antihistamine	16
Bacterial Metabolite	3-oxo-C12HSL (AHL)	(+) T2R38	<i>P. aeruginosa</i> / Quorum sensing	16
Bacterial Metabolite	Quinolones (bacterial)	(+) T2R38	<i>P. aeruginosa</i> / Bacterial signaling	16
Bitter Blocker (Antagonist)	GIV3727	(-) T2R40, T2R43	Synthetic / Research tool	3
Bitter Blocker (Antagonist)	GABA	(-) T2R4	Endogenous / Neurotransmitter	3
Bitter Blocker (Inverse Agonist)	BCML	(-) T2R4	Synthetic / Research tool	3
Bitter Blocker (Antagonist)	3 β -hydroxydihydrocostunolide	(-) T2R46	Wormwood / Natural product	72
Bitter Blocker/Masker	AMP (Adenosine 5'-monophosphate)	(-) T2Rs (mechanism unclear)	Endogenous / Nucleotide	101



plantrica

Bitter Blocker/Masker	Sodium Gluconate	(-) T2Rs (mechanism unclear)	Synthetic / Food additive	101
--------------------------	---------------------	------------------------------------	------------------------------	-----

Note: This table provides illustrative examples. Ligand-receptor interactions can be complex, and activation/inhibition profiles may depend on experimental conditions. (+) indicates activation (agonist), (-) indicates inhibition (antagonist/inverse agonist). AHL = Acyl-Homoserine Lactone.

VI. Evolutionary Significance: Detecting Danger

The evolution of the T2R gene family and the bitter taste system it encodes is intrinsically linked to the fundamental need for organisms to detect and avoid harmful substances in their environment, particularly toxins present in potential food sources.¹ This "toxic substance avoidance" hypothesis provides a strong framework for understanding the selective pressures that have shaped the T2R repertoire across vertebrate evolution.

Plants, in particular, produce a vast arsenal of secondary metabolites (alkaloids, glycosides, terpenoids, etc.) as chemical defenses against herbivores.¹⁶ Many of these defense compounds are toxic and elicit a bitter taste, making T2Rs crucial mediators of plant-animal interactions.¹⁶ The ability to perceive these toxins as bitter provides a direct survival advantage by prompting rejection of the food before lethal doses are ingested.¹

Evidence supporting this evolutionary role comes from comparative genomics and functional studies across diverse vertebrate lineages:

- **Correlation with Diet:** A key finding is the significant correlation observed between the number of functional Tas2r genes in a species' repertoire and the proportion of plants in its diet.²² Herbivores and omnivores, which are more likely to encounter diverse plant toxins, generally possess larger Tas2r repertoires





compared to carnivores, whose diets contain fewer toxic compounds.²² For example, amphibians (many of which consume plants or toxin-containing insects) often have exceptionally large T2R families (sometimes >100 genes), while strict carnivores like dolphins may have lost all functional Tas2r genes.²² This strongly suggests that dietary toxins are a major selective force driving the expansion and maintenance of the Tas2r gene family.²²

- **Gene Family Dynamics (Birth-and-Death Evolution):** The T2R gene family exhibits rapid evolution characterized by frequent gene duplication (birth) and pseudogenization or deletion (death) events.² Lineage-specific expansions and contractions are common, leading to significant differences in repertoire size even between relatively closely related species (e.g., humans vs. mice, or different primate species).²⁰ This dynamic evolution allows species to adapt their bitter sensing capabilities to specific environmental challenges and dietary niches.² For instance, species-specific duplications may lead to receptors specialized for detecting locally relevant toxins.²⁷
- **Signatures of Selection:** Molecular evolutionary analyses often reveal signatures of natural selection acting on T2R genes. While purifying selection acts to maintain the basic structure and function of the receptors (indicated by overall dN/dS ratios < 1)⁹³, evidence for positive selection (dN/dS > 1) is frequently found in specific regions, particularly in the extracellular loops (like ECL2) involved in ligand binding.²⁰ Positive selection suggests adaptive evolution, likely driven by the need to recognize new or changing arrays of bitter toxins in the environment.²⁸ Conversely, relaxation of purifying selection or pseudogenization can occur when the pressure to detect certain toxins decreases, potentially due to dietary shifts or changes in the environment, as suggested for some primate lineages including humans.²⁰ However, balancing selection, which maintains multiple alleles (like the PAV and AVI haplotypes of TAS2R38 in humans), can also operate, suggesting that different sensitivities might be advantageous under different conditions or that heterozygosity itself provides a benefit.⁵⁸
- **Evolutionary Origin:** T2Rs appear to be a relatively recent innovation in vertebrate evolution, emerging in the common ancestor of bony vertebrates





(Euteleostomi) around 400-500 million years ago.² They are absent in cartilaginous fishes (sharks, rays) and jawless fishes.² Interestingly, this timing coincides with the major radiation of vascular plants on land, suggesting a possible co-evolutionary link where the emergence of diverse plant toxins spurred the evolution of the T2R system.² However, the discovery of extraoral T2R functions, including potential sensing of endogenous metabolites or microbial products, raises the alternative possibility that these non-gustatory roles might represent the ancestral function, with the role in taste perception evolving later.¹ Studies on basal vertebrates like coelacanths and sharks suggest that early T2Rs might have had dual roles in detecting both xenobiotics and endogenous compounds like steroids.²⁸

In summary, the evolution of T2R receptors is a compelling example of molecular adaptation driven primarily by the need to navigate the chemical hazards present in food. The dynamic nature of the gene family, the correlation between repertoire size and diet, and the molecular signatures of selection all point towards the crucial role of T2Rs as evolutionary gatekeepers, protecting vertebrates from intoxication and shaping their interactions with the chemical environment. While the protective role against dietary toxins may be somewhat reduced in modern humans with domesticated food sources, the evolutionary legacy of T2Rs continues to influence our biology and health.⁵⁶

VII. T2R Function and Human Health

Beyond their canonical role in taste perception and toxin avoidance, the widespread expression of T2Rs in extraoral tissues implicates them in a variety of physiological processes relevant to human health and disease.¹ Furthermore, genetic variations (polymorphisms) within TAS2R genes, which influence taste sensitivity, are increasingly being associated with variations in health outcomes and disease susceptibility.¹

Key areas where T2R function intersects with human health include:



- Immune Responses and Inflammation:** T2Rs play significant roles in innate immunity, particularly in barrier tissues like the respiratory and gastrointestinal tracts.¹ Activation of T2Rs (e.g., TAS2R38 by bacterial AHLs) in airway epithelial cells triggers NO production, enhancing mucociliary clearance and directly killing bacteria.¹⁶ T2Rs on SCCs stimulate the release of antimicrobial peptides.⁴⁷ Gut tuft cells use T2Rs to detect parasites and initiate type 2 immune responses.¹ Furthermore, T2Rs on immune cells like macrophages and mast cells can modulate phagocytosis and suppress the release of pro-inflammatory cytokines and mediators.¹⁴ Genetic variations in TAS2R genes, especially TAS2R38, have been linked to susceptibility to upper respiratory infections, chronic rhinosinusitis (CRS), and potentially disease severity in conditions like cystic fibrosis and COVID-19.¹⁴ For instance, individuals with the non-functional AVI/AVI genotype of TAS2R38 may have impaired sinonasal innate defense against gram-negative bacteria and potentially worse outcomes in CRS.¹⁶
- Respiratory Function:** Beyond immunity, T2Rs directly impact airway mechanics. Their potent bronchodilatory effect, mediated by relaxation of ASM, positions them as potential therapeutic targets for obstructive lung diseases like asthma and COPD.¹ T2R agonists have shown efficacy in relaxing airways in vitro and in animal models, potentially offering an alternative or adjunct to conventional β_2 -agonists.¹⁰⁶ Additionally, T2R activation inhibits ASM proliferation, suggesting a role in preventing or reversing airway remodeling.¹¹⁴ Genetic variations in TAS2R genes (e.g., TAS2R10, TAS2R14) have been tentatively associated with differences in bronchodilator response and asthma control status in some populations, although more research is needed.⁹⁵
- Metabolism and Dietary Health:** T2Rs in the GI tract, particularly in EECs, link bitter sensing to metabolic regulation.⁴ Stimulation of gut T2Rs can trigger the release of incretin hormones like GLP-1, which enhances insulin secretion and improves glucose tolerance.⁴ They also influence the release of CCK and ghrelin, affecting satiety and gastric motility.¹ Polymorphisms in TAS2R genes, primarily TAS2R38, which influence taste perception, have been associated with food preferences (e.g., aversion to bitter vegetables⁵⁶, preference for sweet foods⁸²),



dietary habits, alcohol consumption ², and potentially body mass index (BMI) or risk of obesity and related metabolic disorders like type 2 diabetes, although findings regarding BMI are often inconsistent.¹⁴ The connection between TAS2R genotype, taste perception, food choice, and metabolic health provides a clear pathway linking genetics to health outcomes.

- **Cancer:** Emerging evidence suggests T2Rs are expressed in various cancer cells and tissues, including head and neck squamous cell carcinoma (HNSCC), pancreatic cancer, breast cancer, and others, often with altered expression levels compared to normal tissue.¹⁴ Intriguingly, activation of T2Rs (e.g., T2R14, T2R38) by bitter agonists has been shown to induce apoptosis (programmed cell death) in several cancer cell lines, often involving nuclear calcium signaling and mitochondrial pathways.¹⁶ Furthermore, higher expression levels of certain T2Rs (e.g., T2R14 in PDAC, overall T2R expression in HNSCC) have been associated with improved patient survival in some cancer types.⁷⁴ Conversely, some studies suggest T2R activation might modulate chemoresistance (e.g., via ABCB1 upregulation linked to T2R38 in pancreatic cancer models ⁷⁴). Polymorphisms in TAS2R genes (e.g., TAS2R38 non-taster status) have also been tentatively linked to increased risk for certain cancers like colorectal cancer, potentially through influences on diet (vegetable intake) or direct effects in the gut.⁶⁹ The role of T2Rs in cancer appears complex and context-dependent but offers potential avenues for biomarkers and therapeutic intervention.
- **Other Conditions:** T2R expression and function are being explored in relation to cardiovascular health (cardiac contractility, vascular tone) ³³, neurological functions (potential role in brain signaling, neuroinflammation) ¹, bone health (inflammation, remodeling) ¹⁰⁴, and potentially other conditions linked to inflammation or chemosensation.

The connection between TAS2R genetics, extraoral function, and disease susceptibility highlights the systemic importance of this receptor family.

Understanding these links opens possibilities for using TAS2R genotype or phenotype (e.g., PTC/PROP tasting status) as biomarkers for disease risk or predicting treatment





responses.¹⁴ It also suggests that modulating T2R activity, either through dietary interventions or pharmacological agents, could offer novel therapeutic strategies for a range of conditions.

VIII. Recent Research Advancements and Future Directions

Research into T2R bitter taste receptors has expanded dramatically beyond their initial discovery as mediators of gustation. Recent advancements focus on elucidating their complex extraoral functions, understanding their structure-function relationships, exploring their roles in health and disease, and investigating their potential as therapeutic targets.¹

Key Areas of Recent Advancement and Ongoing Study:

- **Deciphering Extraoral Functions:** A major focus is unraveling the precise physiological roles of T2Rs in tissues like the airways, gut, immune system, cardiovascular system, and brain.¹ Studies continue to identify novel functions, such as the regulation of apoptosis in airway epithelia and cancer cells¹⁶, the modulation of innate immune responses to specific pathogens (e.g., *P. aeruginosa*, potential link to SARS-CoV-2 outcomes via T2R38 phenotype)¹⁶, and their contribution to metabolic homeostasis via gut hormone release.⁴⁸ Research is moving towards using more physiologically relevant models, including primary cell cultures (e.g., air-liquid interface cultures for airway epithelium) and in vivo studies, to confirm findings from heterologous expression systems.³³
- **Structure-Function Relationships and Ligand Discovery:** Despite the lack of experimental structures, significant progress is being made in understanding how T2Rs recognize ligands and activate signaling pathways through a combination of molecular modeling, site-directed mutagenesis, and functional assays.³ Advanced computational methods, including machine learning algorithms like BitterMatch inspired by recommendation systems, are being developed to predict ligand-receptor interactions and identify novel agonists and antagonists for specific T2Rs, including previously orphan receptors.³¹ These approaches are





expanding the known chemical space for T2R modulators. Identifying the specific residues involved in binding agonists versus antagonists within the same receptor (e.g., T2R4) provides crucial information for rational drug design.³

- **Therapeutic Targeting:** The diverse physiological roles of extraoral T2Rs make them attractive targets for novel therapeutic interventions.¹
 - *Respiratory Diseases:* T2R agonists are being actively investigated as potential treatments for asthma and COPD due to their potent bronchodilatory effects and potential anti-remodeling and anti-inflammatory properties.¹⁰ The redundancy in T2R expression in ASM may offer a therapeutic advantage over single-target approaches like β 2-agonists.¹¹⁵ Targeting T2R-mediated innate immunity (e.g., NO production, AMP secretion) is also being explored for treating respiratory infections like CRS, potentially using topical agonists like diphenhydramine or related compounds.¹⁴
 - *Cancer Therapy:* The ability of T2R agonists to induce apoptosis in certain cancer cells (e.g., HNSCC, pancreatic cancer) suggests their potential use as anticancer agents, possibly delivered topically or systemically.¹⁶ T2R expression levels may also serve as prognostic biomarkers.⁷⁴
 - *Metabolic Disorders:* Modulating gut T2Rs to enhance GLP-1 secretion could be a strategy for managing type 2 diabetes or obesity.⁴⁸
 - *Other Potential Applications:* Targeting T2Rs is being considered for bone disorders (inflammation, anabolism)¹⁰⁴, GI motility disorders⁴⁹, and potentially cardiovascular conditions.³³
- **Drug Discovery and Bitterness Masking:** Understanding T2R-ligand interactions is crucial for predicting and mitigating the bitter taste of pharmaceuticals, thereby improving patient compliance.³ Identifying specific T2R antagonists (bitter blockers) is a key goal.³ Research focuses on discovering novel blockers, elucidating their mechanisms (receptor antagonism vs. other effects), and developing effective formulation strategies (e.g., using GRAS compounds like AMP, sodium gluconate, or targeted delivery systems).³ Computational tools are increasingly used to predict bitterness and screen for potential blockers.³¹ The identification of endogenous modulators like GABA for T2R4 opens new avenues





for understanding physiological regulation and potential blocking strategies.³

- **Evolutionary and Ecological Studies:** Advances in genomics and functional assays are providing deeper insights into the evolution of the T2R family across diverse vertebrate lineages, linking repertoire size and functional diversification to diet, habitat, and specific ecological pressures like toxin exposure or even ontogenetic dietary shifts in amphibians.²

Challenges and Future Perspectives:

Despite rapid progress, challenges remain. The lack of high-resolution T2R structures hinders precise understanding of ligand binding and activation mechanisms, making structure-based drug design difficult.⁸ Deorphanizing the remaining T2Rs and fully characterizing the ligand specificities and potential endogenous ligands for all subtypes is ongoing.³⁹ Translating promising in vitro and animal model findings regarding therapeutic potential into effective human treatments requires overcoming hurdles related to drug delivery, specificity (avoiding off-target effects due to broad T2R expression and ligand promiscuity), and understanding the impact of extensive human genetic variation on T2R function and drug response.¹ Future research will likely focus on obtaining structural information, developing more specific pharmacological tools (agonists and antagonists), further exploring the roles of T2Rs in complex diseases using sophisticated models, and leveraging genetic information for personalized approaches to therapy and bitterness management.

IX. Conclusion

The study of T2R bitter taste receptors has evolved significantly from its origins in gustatory science to encompass a broad range of physiological systems and potential therapeutic applications. Initially identified as the primary sensors for bitter compounds in the oral cavity, serving a critical role in preventing the ingestion of toxins¹, T2Rs are now recognized as a distinct subfamily of GPCRs with unique structural features and activation mechanisms compared to Class A receptors.⁶ The human genome encodes approximately 25 functional T2Rs, exhibiting extensive





genetic polymorphism that underlies individual variations in bitter taste sensitivity and potentially influences dietary habits and health outcomes.²

Perhaps the most transformative discoveries in recent years relate to the widespread expression of T2Rs in extraoral tissues, including the respiratory tract, gastrointestinal system, immune cells, cardiovascular system, and nervous system.¹ In these locations, T2Rs function as versatile chemosensors, detecting not only dietary components but also microbial metabolites and potentially endogenous signals or pharmaceuticals.¹⁶ Their activation triggers diverse, context-dependent physiological responses, including modulation of innate immunity (e.g., mucociliary clearance, antimicrobial peptide release, NO production, phagocytosis), regulation of smooth muscle tone (e.g., potent bronchodilation), control of hormone secretion (e.g., GLP-1, CCK, ghrelin) impacting metabolism and appetite, and even induction of apoptosis in certain cell types.¹

This expanded understanding positions T2Rs as crucial players in maintaining health and responding to pathological challenges. Their involvement in processes ranging from respiratory defense and metabolic regulation to cancer cell fate highlights their potential as novel therapeutic targets.¹ The development of specific T2R agonists (e.g., for bronchodilation or anti-cancer effects) and antagonists (for bitterness masking in pharmaceuticals and food) represents significant translational opportunities.³ However, realizing this potential requires overcoming challenges, including the lack of structural data, the need for more specific pharmacological tools, and a better understanding of the systemic consequences of modulating these broadly expressed receptors, particularly in light of human genetic diversity. Future research focused on structural biology, targeted ligand discovery, and rigorous functional validation in relevant physiological and pathological models will be essential to fully harness the therapeutic promise of the multifaceted T2R family.

Works cited

1. Extraoral bitter taste receptors in health and disease - PMC - PubMed Central,





- accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5299619/>
2. Bitter taste receptors: Genes, evolution and health - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8830313/>
 3. Amino Acid Derivatives as Bitter Taste Receptor (T2R) Blockers - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4155672/>
 4. Extraoral bitter taste receptors in health and disease | Journal of General Physiology, accessed April 27, 2025, <https://rupress.org/jgp/article/149/2/181/43582/Extraoral-bitter-taste-receptors-in-health-and>
 5. A comprehensive map of molecular drug targets - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6314433/>
 6. Structural Basis of Activation of Bitter Taste Receptor T2R1 and ..., accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3195589/>
 7. G protein-coupled receptor - Wikipedia, accessed April 27, 2025, https://en.wikipedia.org/wiki/G_protein-coupled_receptor
 8. Recent advances in structure and function studies on human bitter taste receptors - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/23061795/>
 9. Comparing Class A GPCRs to bitter taste receptors: Structural motifs, ligand interactions and agonist-to-antagonist ratios | Request PDF - ResearchGate, accessed April 27, 2025, https://www.researchgate.net/publication/288824914_Comparing_Class_A_GPCRs_to_bitter_taste_receptors_Structural_motifs_ligand_interactions_and_agonist-to-antagonist_ratios
 10. Constitutive activity of bitter taste receptors (T2Rs) - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/24931200/>
 11. Structure-Function Analyses of Human Bitter Taste Receptors-Where Do We Stand? - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/32993119/>
 12. Structure-Function Analyses of Human Bitter Taste Receptors—Where Do We Stand?, accessed April 27, 2025, <https://www.mdpi.com/1420-3049/25/19/4423>
 13. G Protein-Coupled Receptors in Taste Physiology and Pharmacology - Frontiers, accessed April 27, 2025, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.587664/full>



14. Clinical Associations of Bitter Taste Perception and Bitter Taste Receptor Variants and the Potential for Personalized Healthcare, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9936560/>
15. T2Rs function as bitter taste receptors - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/10761935/>
16. A deadly taste: linking bitter taste receptors and apoptosis - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11946974/>
17. Bitter taste receptors: Genes, evolution and health - Oxford Academic, accessed April 27, 2025, <https://academic.oup.com/emph/article/9/1/431/6395358>
18. Rapid expansion and specialization of the TAS2R bitter taste receptor family in amphibians, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11798467/>
19. The Remarkable Diversity of Vertebrate Bitter Taste Receptors: Recent Advances in Genomic and Functional Studies - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11641376/>
20. Lineage-Specific Loss of Function of Bitter Taste Receptor Genes in Humans and Nonhuman Primates, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC1449719/>
21. Lineage-Specific Expansions and Contractions of the Bitter Taste Receptor Gene Repertoire in Vertebrates | Molecular Biology and Evolution | Oxford Academic, accessed April 27, 2025, <https://academic.oup.com/mbe/article/23/5/964/1058399>
22. Diet Shapes the Evolution of the Vertebrate Bitter Taste Receptor Gene Repertoire - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3907052/>
23. Diet Shapes the Evolution of the Vertebrate Bitter Taste Receptor Gene Repertoire, accessed April 27, 2025, https://www.researchgate.net/publication/258349245_Diet_Shapes_the_Evolution_of_the_Vertebrate_Bitter_Taste_Receptor_Gene_Repertoire
24. Evolutionary relationships of the Tas2r receptor gene families in mouse and human | Physiological Genomics, accessed April 27, 2025, <https://journals.physiology.org/doi/10.1152/physiolgenomics.00060.2003>
25. Probing the Evolutionary History of Human Bitter Taste Receptor Pseudogenes by Restoring Their Function - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5850805/>
26. Genetics of Taste Receptors - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4764331/>



27. Comprehensive Analysis of Mouse Bitter Taste Receptors Reveals Different Molecular Receptive Ranges for Orthologous Receptors in Mice and Humans - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4946946/>
28. At the Root of T2R Gene Evolution: Recognition Profiles of Coelacanth and Zebrafish Bitter Receptors - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7851594/>
29. Role of the G-Protein Subunit α -Gustducin in Taste Cell Responses to Bitter Stimuli, accessed April 27, 2025, https://www.researchgate.net/publication/5389608_Role_of_the_G-Protein_Subunit_a-Gustducin_in_Taste_Cell_Responses_to_Bitter_Stimuli
30. Predicted structure of fully activated human bitter taste receptor TAS2R4 complexed with G protein and agonists | QRB Discovery, accessed April 27, 2025, <https://www.cambridge.org/core/journals/qrb-discovery/article/predicted-structure-of-fully-activated-human-bitter-taste-receptor-tas2r4-complexed-with-g-protein-and-agonists/252D0363D3638C89D654D6B5AB4A1CD5>
31. Inhibiting a promiscuous GPCR: iterative discovery of bitter taste receptor ligands - bioRxiv, accessed April 27, 2025, <https://www.biorxiv.org/content/10.1101/2022.11.24.517821v1.full.pdf>
32. Bitter taste receptors: Novel insights into the biochemistry and pharmacology - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/26995065/>
33. A Bitter Taste in Your Heart - Frontiers, accessed April 27, 2025, <https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00431/full>
34. Taste receptor - Wikipedia, accessed April 27, 2025, https://en.wikipedia.org/wiki/Taste_receptor
35. Activation mechanism of the G protein-coupled sweet receptor heterodimer with sweeteners and allosteric agonists | PNAS, accessed April 27, 2025, <https://www.pnas.org/doi/10.1073/pnas.1700001114>
36. G Protein-Coupled Receptors in Taste Physiology and Pharmacology - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/33390961/>
37. Characterization of Ligands for Fish Taste Receptors - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6672760/>
38. The Bitter Taste Receptor Agonist Quinine Reduces Calorie Intake and Increases the Postprandial Release of Cholecystokinin in Healthy Subjects - Journal of Neurogastroenterology and Motility, accessed April 27, 2025,



- <https://www.jnmjournal.org/journal/view.html?uid=1018&vmd=Full>
39. The taste for health: the role of taste receptors and their ligands in the complex food/health relationship - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11169839/>
 40. Functional Interaction between T2R Taste Receptors and G-Protein α Subunits Expressed in Taste Receptor Cells - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6740443/>
 41. Functional Interaction between T2R Taste Receptors and G-Protein α Subunits Expressed in Taste Receptor Cells | Journal of Neuroscience, accessed April 27, 2025, <https://www.jneurosci.org/content/23/19/7376>
 42. Expression of bitter taste receptors of the T2R family in the gastrointestinal tract and enteroendocrine STC-1 cells - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC122375/>
 43. Clinical Role of Extraoral Bitter Taste Receptors - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7404188/>
 44. Characterization and solubilization of bitter-responsive receptors that couple to gustducin | PNAS, accessed April 27, 2025, <https://www.pnas.org/doi/10.1073/pnas.95.15.8933>
 45. Taste Receptors in the Gastrointestinal Tract. I. Bitter taste receptors and α -gustducin in the mammalian gut - American Journal of Physiology, accessed April 27, 2025, <https://journals.physiology.org/doi/full/10.1152/ajpgi.00073.2006>
 46. Role of the bitter taste receptor T2R38 in upper respiratory infection and chronic rhinosinusitis - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5902169/>
 47. Human T2R38 Bitter Taste Receptor Expression and COVID-19: From Immunity to Prognosis - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10073923/>
 48. Theranostics Mechanisms and novel therapeutic roles of bitter taste receptors in diseases, accessed April 27, 2025, <https://www.thno.org/v15p3961.pdf>
 49. Bitter taste receptors and α -gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptying | PNAS, accessed April 27, 2025, <https://www.pnas.org/doi/10.1073/pnas.1011508108>
 50. Functional characterization of human bitter taste receptors - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC1876383/>
 51. Review: A Novel Family of Mammalian Taste Receptors - Biology, accessed April 27, 2025,



- <https://www.bio.davidson.edu/courses/molbio/molstudents/spring2000/kazama/restricted/review.html>
52. Association of Bitter Taste Receptors with Obesity and Diabetes and Their Role in Related Tissues - MDPI, accessed April 27, 2025, <https://www.mdpi.com/2813-2564/2/4/17>
 53. The Remarkable Diversity of Vertebrate Bitter Taste Receptors: Recent Advances in Genomic and Functional Studies - MDPI, accessed April 27, 2025, <https://www.mdpi.com/1422-0067/25/23/12654>
 54. Genetic variation in taste receptor pseudogenes provides evidence for a dynamic role in human evolution - ResearchGate, accessed April 27, 2025, https://www.researchgate.net/publication/265607432_Genetic_variation_in_taste_receptor_pseudogenes_provides_evidence_for_a_dynamic_role_in_human_evolution
 55. Evolution of Bitter Taste Receptors in Humans and Apes - Oxford Academic, accessed April 27, 2025, <https://academic.oup.com/mbe/article/22/3/432/1075880>
 56. Global population genetics and diversity in the TAS2R bitter taste receptor family - Frontiers, accessed April 27, 2025, <https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.952299/full>
 57. Molecular Receptive Ranges of Human TAS2R Bitter Taste Receptors - Oxford Academic, accessed April 27, 2025, <https://academic.oup.com/chemse/article/35/2/157/485156>
 58. (PDF) The roles of genes in the bitter taste - ResearchGate, accessed April 27, 2025, https://www.researchgate.net/publication/338143802_The_roles_of_genes_in_the_bitter_taste
 59. Receptor Polymorphism and Genomic Structure Interact to Shape Bitter Taste Perception | PLOS Genetics, accessed April 27, 2025, <https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1005530>
 60. An update on extra-oral bitter taste receptors - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8529754/>
 61. Bitter taste receptors along the gastrointestinal tract: comparison between humans and rodents - Frontiers, accessed April 27, 2025, <https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1215889/full>
 62. Rapid expansion and specialization of the TAS2R bitter taste receptor family in



- amphibians, accessed April 27, 2025,
<https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1011533>
63. Evolution of bitter receptor genes and ontogenetic dietary shift in a frog - PNAS, accessed April 27, 2025, <https://www.pnas.org/doi/10.1073/pnas.2218183120>
 64. Evolution of bitter receptor genes and ontogenetic dietary shift in a frog - ResearchGate, accessed April 27, 2025,
https://www.researchgate.net/publication/368475694_Evolution_of_bitter_receptor_genes_and_ontogenetic_dietary_shift_in_a_frog
 65. Relationships between Bitter Taste Receptor Gene Evolution, Diet, and Gene Repertoire in Primates - Oxford Academic, accessed April 27, 2025,
<https://academic.oup.com/gbe/article/16/5/evae104/7674237>
 66. Diet Shapes the Evolution of the Vertebrate Bitter Taste Receptor Gene Repertoire - Oxford Academic, accessed April 27, 2025,
<https://academic.oup.com/mbe/article-pdf/31/2/303/13171521/mst219.pdf>
 67. Global population genetics and diversity in the TAS2R bitter taste receptor family - Frontiers, accessed April 27, 2025,
<https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.952299/pdf>
 68. (PDF) Positive selection drives the evolution of a primate bitter taste receptor gene, accessed April 27, 2025,
https://www.researchgate.net/publication/350322430_Positive_selection_drives_the_evolution_of_a_primate_bitter_taste_receptor_gene
 69. Association Between TAS2R38 Gene Polymorphisms and Colorectal Cancer Risk: A Case-Control Study in Two Independent Populations of Caucasian Origin - PubMed Central, accessed April 27, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC3107225/>
 70. Mechanisms and novel therapeutic roles of bitter taste receptors in diseases - PMC, accessed April 27, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC11980658/>
 71. A Bitter Taste in Your Heart - PMC - PubMed Central, accessed April 27, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC7225360/>
 72. Receptor Agonism and Antagonism of Dietary Bitter Compounds - Journal of Neuroscience, accessed April 27, 2025,
<https://www.jneurosci.org/content/31/41/14775>
 73. Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2 - Ingenta Connect, accessed April 27, 2025,





- <https://www.ingentaconnect.com/contentone/govi/pharmaz/2021/00000076/f0020002/art00001?crawler=true&mimetype=application/pdf>
74. Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9728555/>
 75. BitterMatch: Recommendation systems for matching molecules with bitter taste receptors - bioRxiv, accessed April 27, 2025, <https://www.biorxiv.org/content/10.1101/2022.01.13.476205v2.full.pdf>
 76. Taste Masking of Bitter Drugs in Pharmaceutical Suspension: A Review - Asian Journal of Pharmacy and Technology, accessed April 27, 2025, <https://ajptonline.com/HTMLPaper.aspx?Journal=Asian%20Journal%20of%20Pharmacy%20and%20Technology;PID=2023-13-4-6>
 77. Genomic organization, expression, and function of bitter taste receptors (T2R) in mouse and rat - American Journal of Physiology, accessed April 27, 2025, <https://journals.physiology.org/doi/10.1152/physiolgenomics.00030.2005>
 78. Genomic drift and copy number variation of sensory receptor genes in humans - PNAS, accessed April 27, 2025, <https://www.pnas.org/doi/pdf/10.1073/pnas.0709956104>
 79. TAS2R38 Bitter Taste Receptor Polymorphisms in Patients with Chronic Rhinosinusitis with Nasal Polyps Preliminary Data in Polish Population - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/38255273/>
 80. (PDF) Rare haplotypes of the gene TAS2R38 confer bitter taste sensitivity in humans, accessed April 27, 2025, https://www.researchgate.net/publication/282278788_Rare_haplotypes_of_the_gene_TAS2R38_confer_bitter_taste_sensitivity_in_humans
 81. TAS2R38 Predisposition to Bitter Taste Associated with Differential Changes in Vegetable Intake in Response to a Community-Based Dietary Intervention | G3 Genes|Genomes - Oxford Academic, accessed April 27, 2025, <https://academic.oup.com/g3journal/article/8/6/2107/6028065>
 82. 5726 - Gene ResultTAS2R38 taste 2 receptor member 38 [(human)] - NCBI, accessed April 27, 2025, <https://www.ncbi.nlm.nih.gov/gene/5726>
 83. PTC bitter taste genetic polymorphism, food choices, physical growth in body height and body fat related traits among adolescent girls from Kangra Valley, Himachal Pradesh (India) - ResearchGate, accessed April 27, 2025, https://www.researchgate.net/publication/255788038_PTC_bitter_taste_genetic_polymorphism_food_choices_physical_growth_in_body_height_and_body_fat_rela





- [ted traits among adolescent girls from Kangra Valley Himachal Pradesh India](#)
84. TAS2R38 - Wikipedia, accessed April 27, 2025, <https://en.wikipedia.org/wiki/TAS2R38>
 85. The roles of genes in the bitter taste - AIMS Press, accessed April 27, 2025, <https://www.aimspress.com/article/10.3934/genet.2019.4.88/figure.html>
 86. Genetic, Functional, and Phenotypic Diversity in TAS2R38-Mediated Bitter Taste Perception | Chemical Senses | Oxford Academic, accessed April 27, 2025, <https://academic.oup.com/chemse/article/38/6/475/299074>
 87. Genetic Variation in the TAS2R38 Bitter Taste Receptor and Smoking Behaviors | PLOS One, accessed April 27, 2025, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164157>
 88. Validation Study: Evaluating Phenotypic Expression of Bitter Taste Receptors, accessed April 27, 2025, <https://clinmedjournals.org/articles/jor/journal-of-otolaryngology-and-rhinology-jor-7-110.php?jid=jor>
 89. The roles of genes in the bitter taste - Thieme Connect, accessed April 27, 2025, <https://www.thieme-connect.com/products/ejournals/pdf/10.3934/genet.2019.4.88.pdf>
 90. Association between Genetic Variation in the TAS2R38 Bitter Taste Receptor and Propylthiouracil Bitter Taste Thresholds among Adults Living in Japan Using the Modified 2AFC Procedure with the Quest Method - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10222862/>
 91. Insights into the impact of genetic variation in bitter taste sensitivity on young children's acceptance of vegetables and body mass index: an update until 2010 - OAText, accessed April 27, 2025, <https://www.oatext.com/Insights-into-the-impact-of-genetic-variation-in-bitter-taste-sensitivity-on-young-childrens-acceptance-of-vegetables-and-body-mass-index-an-update-until-2010.php>
 92. Cilia Stimulatory and Antibacterial Activities of T2R Bitter Taste Receptor Agonist Diphenhydramine: Insights into Repurposing Bitter Drugs for Nasal Infections - MDPI, accessed April 27, 2025, <https://www.mdpi.com/1424-8247/15/4/452>
 93. Signatures of Natural Selection in a Primate Bitter Taste Receptor - ResearchGate, accessed April 27, 2025, https://www.researchgate.net/publication/51983401_Signatures_of_Natural_Selection_in_a_Primate_Bitter_Taste_Receptor
 94. T2R bitter taste receptors regulate apoptosis and may be associated with survival





- in head and neck squamous cell carcinoma, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8978516/>
95. Association between Polymorphisms in Bitter Taste Receptor Genes and Clinical Features in Korean Asthmatics - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/26812163/>
 96. A gene-wide investigation on polymorphisms in the taste receptor 2R14 (TAS2R14) and susceptibility to colorectal cancer - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC2893173/>
 97. A meta-analysis on polymorphic trait of taste perception mediated by TAS2R38 genotype, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/38815112/>
 98. HSP90 modulates T2R bitter taste receptor nitric oxide production and innate immune responses in human airway epithelial cells a - bioRxiv, accessed April 27, 2025, <https://www.biorxiv.org/content/10.1101/2021.11.16.468387v3.full.pdf>
 99. Does phenotypic expression of bitter taste receptor T2R38 show association with COVID-19 severity? - PMC - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7461007/>
 100. Extraoral bitter taste receptors as mediators of off-target drug effects - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC3509062/>
 101. Bitter-blockers as a taste masking strategy: a systematic review towards their utility in pharmaceuticals - UCL Discovery, accessed April 27, 2025, <https://discovery.ucl.ac.uk/id/eprint/10114160/1/1-s2.0-S0939641120303179-main.pdf>
 102. Bitter-blockers as a taste masking strategy: A systematic review towards their utility in pharmaceuticals | Request PDF - ResearchGate, accessed April 27, 2025, https://www.researchgate.net/publication/346515411_Bitter-blockers_as_a_taste_masking_strategy_A_systematic_review_towards_their_utility_in_pharmaceuticals
 103. bitter taste masking: Topics by Science.gov, accessed April 27, 2025, <https://www.science.gov/topicpages/b/bitter+taste+masking>
 104. Bitter Taste Receptor as a Therapeutic Target in Orthopaedic Disorders - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/33679130/>
 105. Identification of ligands for two human bitter T2R receptors - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/15337684/>
 106. The bitter taste receptor (TAS2R) agonists denatonium and chloroquine display distinct patterns of relaxation of the guinea pig trachea - American Journal of Physiology, accessed April 27, 2025, <https://journals.physiology.org/doi/10.1152/ajplung.00205.2012>





107. Structure-Function Analyses of Human Bitter Taste Receptors—Where Do We Stand? - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7582848/>
108. Extraoral expression and characterization of bitter taste receptors in *Astyanax mexicanus* (Mexican tetra fish) - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9447421/>
109. Bitter Taste Receptors (T2Rs) are Sentinels that Coordinate Metabolic and Immunological Defense Responses - PubMed Central, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7963268/>
110. Extraoral bitter taste receptors as mediators of off-target drug effects - ResearchGate, accessed April 27, 2025, https://www.researchgate.net/publication/230828939_Extraoral_bitter_taste_receptors_as_mediators_of_off-target_drug_effects
111. Chemoinformatics View on Bitter Taste Receptor Agonists in Food - ACS Publications, accessed April 27, 2025, <https://pubs.acs.org/doi/10.1021/acs.jafc.1c05057>
112. The pharmacology of bitter taste receptors and their role in human airways - PubMed, accessed April 27, 2025, <https://pubmed.ncbi.nlm.nih.gov/26272040/>
113. Taste Receptors: The Gatekeepers of the Airway Epithelium - MDPI, accessed April 27, 2025, <https://www.mdpi.com/2073-4409/10/11/2889>
114. Bitter Taste Receptors for Asthma Therapeutics - Frontiers, accessed April 27, 2025, <https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.00884/full>
115. Therapeutic Potential and Challenges of Bitter Taste Receptors on Lung Cells - PMC, accessed April 27, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7530014/>
116. Toward the Identification of Extra-Oral TAS2R Agonists as Drug Agents for Muscle Relaxation Therapies via Bioinformatics-Aided Screening of Bitter Compounds in Traditional Chinese Medicine - Frontiers, accessed April 27, 2025, <https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.00861/full>
117. Antimitogenic effect of bitter taste receptor agonists on airway smooth muscle cells, accessed April 27, 2025, <https://journals.physiology.org/doi/full/10.1152/ajplung.00373.2015>
118. www.mdpi.com, accessed April 27, 2025, <https://www.mdpi.com/2073-4409/10/11/2889#:~:text=T2Rs%20are%20expresse>





- [d%20on%20multiple,which%20leads%20to%20bacterial%20clearance.](#)
119. Taste Receptor Polymorphisms and Immune Response - Frontiers, accessed April 27, 2025,
<https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2018.00064/pdf>
 120. T2R bitter taste receptor expression in airway cell cilia.... - ResearchGate, accessed April 27, 2025,
https://www.researchgate.net/figure/T2R-bitter-taste-receptor-expression-in-airway-cell-cilia-Representative-images-of-cilia_fig2_360612528
 121. Neuroimmune recognition and regulation in the respiratory system, accessed April 27, 2025, <https://publications.ersnet.org/content/errev/33/172/240008>
 122. Citations to Bitter and sweet taste receptors regulate human upper respiratory innate immunity - JCI, accessed April 27, 2025,
<https://www.jci.org/articles/view/72094/citations>
 123. Bitter and sweet taste receptors regulate human upper respiratory innate immunity - JCI, accessed April 27, 2025, <https://www.jci.org/articles/view/72094>
 124. A singular shark bitter taste receptor provides insights into the evolution of bitter taste perception - PMC, accessed April 27, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC10691231/>
 125. Masking Bitter Taste by Molecules | Request PDF - ResearchGate, accessed April 27, 2025,
https://www.researchgate.net/publication/225654313_Masking_Bitter_Taste_by_Molecules
 126. Identification of Bitterness-Masking Compounds from Cheese | Journal of Agricultural and Food Chemistry - ACS Publications, accessed April 27, 2025,
<https://pubs.acs.org/doi/10.1021/jf300563n>
 127. Computational Studies on T2Rs Agonist-Based Anti-COVID-19 Drug Design - Frontiers, accessed April 27, 2025,
<https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2021.637124/full>
 128. At the Root of T2R Gene Evolution: Recognition Profiles of Coelacanth and Zebrafish Bitter Receptors - PubMed, accessed April 27, 2025,
<https://pubmed.ncbi.nlm.nih.gov/33355666/>
 129. Physical Approaches to Masking Bitter Taste: Lessons from Food and Pharmaceuticals - PubMed Central, accessed April 27, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC4898047/>





130. Taste Masking Techniques in the Pharmaceutical Industry, accessed April 27, 2025,
<https://www.americanpharmaceuticalreview.com/Featured-Articles/163483-Taste-Masking-Techniques-in-the-Pharmaceutical-Industry/>
131. Positive selection on the human genome | Human Molecular Genetics - Oxford Academic, accessed April 27, 2025,
https://academic.oup.com/hmg/article/13/suppl_2/R245/619711
132. Regulatory T Cells Found To Safeguard Brain Health, Memory Formation, accessed April 27, 2025,
<https://hms.harvard.edu/news/regulatory-t-cells-found-safeguard-brain-health-memory-formation>
133. An opinion on the debatable function of brain resident immune protein, T-cell receptor beta subunit in the central nervous system, accessed April 27, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC9795316/>
134. Role of the Immune System in the Development of the Central Nervous System - Frontiers, accessed April 27, 2025,
<https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.00916/full>
135. How Does the Immune System Enter the Brain? - Frontiers, accessed April 27, 2025,
<https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.805657/full>
136. Large Language Models in Drug Discovery and Development: From Disease Mechanisms to Clinical Trials - arXiv, accessed April 27, 2025,
<https://arxiv.org/html/2409.04481>
137. Target Identification & Validation in Drug Discovery & Development - Danaher Life Sciences, accessed April 27, 2025,
<https://lifesciences.danaher.com/us/en/library/target-identification-validation-drug-discovery.html>
138. Artificial intelligence in drug discovery and development - PMC - PubMed Central, accessed April 27, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC7577280/>

